Blog
Legal resources, litigation updates, and guidance on the claims we review.
Depo-Provera Settlement Reports: What They Mean for Claimants
Reports describe an agreement to resolve federal Depo-Provera meningioma claims. Here is what a settlement agreement means at this stage, what remains unresolved, and what records matter if you took the shot and were later diagnosed with a meningioma.
GLP-1 Vision Loss Claims: What NAION Lawsuits Allege
Lawsuits have been reported alleging that GLP-1 medications like Ozempic and Wegovy are linked to NAION, a sudden form of optic nerve injury. Here is what the research reports, what plaintiffs allege, and what the symptoms look like.
Beyond CRE: VRE and Other Superbug Claims After ERCP
A newly reported Olympus lawsuit alleges a fatal VRE infection following ERCP, a reminder that duodenoscope infection claims are not limited to carbapenem-resistant organisms. Here is what these individually filed cases allege and what records matter.
Failure to Warn: What Dupixent Lymphoma Lawsuits Allege
Dupixent lawsuits center on a failure-to-warn theory: that patients and prescribing doctors were not told about a possible cutaneous T-cell lymphoma risk. Here is what those allegations say, and what remains unproven.
Section 230 and Design Claims in Social Media Addiction Cases
Courts handling adolescent social media addiction claims have drawn a line between suing over content and suing over platform design. Here is what that distinction means for parents weighing a claim on behalf of a teen.
Why PowerPort Juries Won't Hear About Bard's IVC Filters
Legal trade press has reported that the judge overseeing the Bard PowerPort litigation limited evidence about Bard's separate IVC filter problems. Here is what that kind of evidentiary ruling means, and what juries in port catheter cases actually hear.
NAION Vision Loss Claims Move to Center of GLP-1 Litigation
Reports indicate that early discovery in GLP-1 vision loss lawsuits is focusing on NAION, a form of sudden optic nerve injury. Here is what patients and families should understand about the condition, the research, and the litigation.
Dupixent CTCL Cases Centralized: What MDL Consolidation Means
Federal Dupixent lymphoma lawsuits have been centralized into a single multidistrict litigation. Here is what that procedural step means for people diagnosed with cutaneous T-cell lymphoma — and what it does not decide.
Port Catheter Infection and Sepsis Claims: What Patients Should Know
An overview of the bloodstream infection and sepsis allegations in the Bard PowerPort litigation, including how catheter-related infections are diagnosed and which medical records tend to matter most.
Preserving Roblox Chat Logs and Account Records for a Claim
A practical guide for parents and guardians on saving Roblox chat history, account data, Robux purchase records, and related documentation while child safety litigation against Roblox Corporation moves forward. Includes what to do first if a child is in danger.
Reusable Duodenoscopes and the Push Toward Disposable Designs
A newly reported lawsuit alleges a fatal infection after an ERCP performed with a reusable duodenoscope. Here is what the reported FDA transition toward disposable designs involves, and how these individually filed claims work.
When One Platform Settles: What Parents Should Understand
Reports of settlements by individual social media companies and appeals of early verdicts have raised questions for families with pending claims. Here is what a partial settlement does and does not mean for a minor's case.
NAION Vision Loss Claims and GLP-1 Litigation Explained
An overview of NAION, the reported association between GLP-1 medications and sudden vision loss, and how those allegations are being raised in ongoing litigation. Educational information for patients researching their own eye injury.
After the First Trials: What Comes Next for Pending Teen Claims
Reported verdicts and a settlement in the first social media addiction cases have changed the landscape for families with pending claims. Here is what bellwether trials actually decide, and what they do not, for your child's case.
Mycosis Fungoides, Sézary Syndrome, and Dupixent Claims Explained
A plain-language look at cutaneous T-cell lymphoma, why mycosis fungoides is often mistaken for eczema, and the two theories plaintiffs have raised in the Dupixent CTCL litigation.
Roblox Safety Updates: What They Mean for Your Family's Claim
Roblox has publicized new age-check and parental-control measures while facing child safety lawsuits and regulatory scrutiny. Here is what those changes mean for parents considering a claim, and what records to preserve.
The Next Bard PowerPort Bellwether: Fracture Claims Take Center Stage
The first Bard PowerPort bellwether trial ended in a defense verdict on infection allegations. Reports indicate the next trial focuses on catheter fracture and migration — here is what that difference means for patients following the litigation.
Why the Duodenoscope Elevator Mechanism Drives Infection Lawsuits
Lawsuits over infections after ERCP focus on the duodenoscope's reusable elevator mechanism and its cleaning instructions. Here is what those allegations claim, what the FDA has said, and how these individually filed claims work.
Depo-Provera Meningioma Updates for Patients
Recent Depo-Provera headlines have focused on meningioma warnings, medical studies, and active litigation. This guide explains what patients should understand without overstating what courts or studies have decided.
After the First PowerPort Bellwether Verdict: What Comes Next
A jury returned a defense verdict in the first Bard PowerPort bellwether trial over infection claims, and a second bellwether focused on catheter fracture has been reported as next. Here is what those trials decide, what they do not, and what it means for people with implanted port claims.
Diagnosed Before Dupixent? The Masking Claim Explained
Dupixent CTCL lawsuits plead two separate theories: that the drug may cause or accelerate cutaneous T-cell lymphoma, and that it may mask early lymphoma symptoms and delay diagnosis. Here is what that second theory means for patients diagnosed before, during, or after treatment.
Endoscope Infection Claims Are Filed Individually, Not Consolidated
Duodenoscope and endoscope infection lawsuits against Olympus, Fujifilm and Pentax are pursued as individual cases in state and federal courts — not through an MDL or class action. Here is what that means for patients and families.
First Social Media Addiction Verdicts: What Parents Should Know
Reported verdicts against Meta and YouTube, plus settlements by TikTok and Google ahead of trial, have moved social media addiction litigation into a new phase. Here is what those developments do and do not mean for a parent considering a claim.
State Roblox Lawsuits and Your Family's Own Claim
State attorneys general have sued Roblox over child safety, and some have reached reported settlements. Here is what those government actions do and do not do for your family, and how private claims are being pursued.
Depo-Provera: FDA Adds Brain Tumor Warning to Label
Learn about the recent FDA label change for Depo-Provera, including a new warning about the potential risk of meningioma brain tumors. This update impacts users and ongoing litigation.
GLP-1 Vision Loss Lawsuits: What You Need to Know
Explore the growing concerns and ongoing litigation surrounding GLP-1 medications like Ozempic and Wegovy, specifically addressing allegations of vision loss.
FDA Adds Meningioma Warning to Depo-Provera Label
The FDA-approved Depo-Provera label now addresses reported meningiomas after repeated use. Learn what the warning says, which symptoms warrant medical attention, and how the update may affect litigation.
Depo-Provera: Understanding the New FDA Brain Tumor Warning
The FDA has reportedly updated the Depo-Provera label to include a warning about meningioma, a type of brain tumor. This post explores what this warning means for users and the status of related litigation.
Depo-Provera and Meningioma: Understanding the Latest Lawsuit Information
Explore the emerging legal landscape surrounding Depo-Provera use and meningioma diagnoses. Learn about recent developments and what women should know.
Ozempic and GLP-1 Drugs: Understanding Gastroparesis and Bowel Obstruction Lawsuits
Explore the potential risks of GLP-1 medications like Ozempic and Wegovy, including gastroparesis and bowel obstruction, and understand the ongoing litigation addressing these serious side effects.
Depo-Provera Litigation Update: Meningioma Claims and Patient Awareness
Explore the latest in Depo-Provera litigation concerning meningioma brain tumors. Learn about the risks and what women who have used the drug should know.
FDA Depo-Provera Warning and Brain Tumor Lawsuits
Learn what the FDA’s updated Depo-Provera meningioma warning may mean for long-term users considering a brain tumor lawsuit in 2026. This guide explains the medical issue, litigation context, and records that may matter.
Depo-Provera Bellwether Trial Date and FDA Warning
Learn what the December 2026 Depo-Provera bellwether trial date may mean for women pursuing meningioma claims after the FDA added a brain tumor warning. This guide explains the litigation timeline, medical evidence, and practical next steps.
Wrongful Death from Compounded Semaglutide: Proving Contamination Claims
After April 2026 contamination reports, families pursuing wrongful death claims from compounded semaglutide face complex causation and liability questions. Learn what records to secure, how to prove pharmacy negligence, and whether federal or state court is your best path.
Federal Preemption After FDA Warning: What It Means for Meningioma Claims
The FDA's updated Depo-Provera meningioma warning significantly weakens Pfizer's federal preemption defense. Learn how the pending MDL ruling on preemption could reshape liability and valuations for women diagnosed in 2026.
NAION and GLP-1 Drugs: What Vision Loss Claims Involve
An educational look at NAION, the sudden vision loss condition now at the center of GLP-1 injury lawsuits involving Ozempic, Wegovy, and Saxenda, and what the reported research and early litigation activity actually say.
June 2026 Depo-Provera Hearings and Case Timing
The June 2026 causation hearings in the Depo-Provera litigation could shape how quickly meningioma claims move forward. Here is what evidence rulings may change, what they may not, and how to prepare your case timeline.
2026 GLP-1 Vision Claims: NAION vs Diabetic Eye Disease
NAION and diabetic eye disease are not the same injury, and the distinction can materially affect a 2026 GLP-1 vision loss lawsuit. Learn which ophthalmology records, test results, and timeline details can strengthen an Ozempic or Wegovy claim.
Telehealth Semaglutide and Lawsuit Eligibility: The Novo Nordisk-Hims Deal Explained
Learn how the Novo Nordisk and Hims & Hers partnership affects compounded semaglutide users and potential GLP-1 injury lawsuit eligibility in 2026.
Depo-Provera Users Need to Know: What the FDA's New Label Warning Means for Monitoring and Screening
The FDA's updated Depo-Provera label includes guidance on monitoring and screening. Learn what women who used this contraceptive need to do to protect their health.
Pancreatitis and GLP-1 Drugs: Symptoms, Diagnosis, and Legal Options
Learn how GLP-1 medications like Ozempic increase pancreatitis risk, recognize warning signs, and understand your legal options if you've been harmed.
Depo-Provera and Meningioma: A Timeline of FDA Warnings and Studies
A chronological timeline of the Depo-Provera meningioma link — from early research through the BMJ study, FDA label update, and current litigation milestones.
The Depo-Provera MDL: Case Count, Timeline, and What to Expect
Track the Depo-Provera meningioma MDL: current case count, court proceedings, bellwether selection, Rule 702 hearings, and the December 2026 pilot trial timeline.
Depo-Provera Meningioma Settlements: What Comparable Cases Tell Us
What can comparable pharmaceutical mass tort settlements tell us about potential Depo-Provera meningioma case values? Analysis of factors affecting compensation and timeline expectations.
Depo-Provera Pilot Trial December 2026: What It Means for Your Case
The first Depo-Provera meningioma pilot trial is set for December 2026. Learn what bellwether trials are, what's being argued, potential outcomes, and the impact on settlement.
Depo-Provera vs. Ozempic Lawsuit: Key Differences Explained
Compare the Depo-Provera meningioma lawsuit and the GLP-1/Ozempic lawsuit side by side — drug type, injuries, MDL status, case counts, and settlement timelines.
Can I File a Depo-Provera Lawsuit if I Used It Years Ago?
Wondering if you can still file a Depo-Provera meningioma lawsuit if you used the drug years or decades ago? Learn how the discovery rule and statutes of limitations work.
Which GLP-1 Drugs Are Included in the Ozempic Lawsuit?
Find out which GLP-1 receptor agonist drugs are covered in the Ozempic lawsuit, what injuries qualify, and how the MDL process works for affected patients.
Gastric Emptying Study: Why It Matters for Your Ozempic Claim
Learn what a gastric emptying study (GES) is, how it's performed, and why it's the key diagnostic test for strengthening your Ozempic gastroparesis legal claim.
Mounjaro, Wegovy, Trulicity: GLP-1 Lawsuits Beyond Ozempic
The GLP-1 litigation extends well beyond Ozempic. Learn about lawsuits involving Mounjaro, Wegovy, Trulicity, Saxenda, and Rybelsus — including injury profiles and case counts.
GLP-1 Medications Compared: Ozempic vs. Wegovy vs. Mounjaro vs. Trulicity
A side-by-side comparison of GLP-1 medications involved in the mass tort litigation — Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda, and Rybelsus — including active ingredients, manufacturers, and lawsuit status.
How Mass Tort Lawsuits Work: A Plain-English Guide
A clear, jargon-free guide to mass tort lawsuits: how MDLs differ from class actions, what bellwether trials are, how settlements work, and what clients should expect.
Ozempic and Bowel Obstruction: Symptoms, Risks, and Legal Options
Bowel obstruction is a serious, potentially life-threatening side effect of GLP-1 drugs like Ozempic. Learn about symptoms, emergency risks, and legal claims for affected patients.
Ozempic Gallbladder Disease: Qualifying Injuries in the GLP-1 MDL
Gallstones, cholecystitis, and cholecystectomy after taking Ozempic or other GLP-1 drugs — learn about qualifying gallbladder injuries, FDA warnings, and your legal options.
Ozempic and Vision Loss (NAION): The Emerging Legal Claims
A Harvard study links GLP-1 drugs like Ozempic to NAION, a serious form of sudden vision loss. Learn about the condition, the research, and your legal options.
Already Diagnosed? How to Start Your Mass Tort Claim
A step-by-step guide to filing a mass tort claim after a diagnosis — from gathering documents to filing your case. Covers both Depo-Provera meningioma and GLP-1 drug claims.
What Is a Meningioma? Understanding the Brain Tumor Linked to Depo-Provera
A comprehensive medical explainer on meningioma brain tumors: types, symptoms, diagnosis, treatment options, and the established link to Depo-Provera contraceptive injections.
Do You Qualify for the Depo-Provera Meningioma Lawsuit?
A straightforward guide to determining whether you qualify to file a Depo-Provera meningioma claim. Learn the key eligibility criteria.
FDA Warns: Depo-Provera Linked to Meningioma Brain Tumors
In December 2025, the FDA added a warning to Depo-Provera's label linking the contraceptive injection to meningioma brain tumors. Learn what this means for your legal rights.
Gastroparesis After Ozempic: Symptoms, Diagnosis, and Legal Options
If you developed gastroparesis or other serious stomach problems after taking Ozempic, Wegovy, or Mounjaro, you may have legal options. Here's what you need to know.
Ozempic Lawsuit Update: What You Need to Know in 2026
Over 3,300 cases are now pending in the GLP-1 litigation. Here's where things stand with the Ozempic, Wegovy, and Mounjaro lawsuits as of 2026.